SCHEDULE 13G/A: BlackRock Reports Reduced 3.0% Stake in Mersana Therapeutics

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting beneficial ownership of 3.0% of Mersana Therapeutics Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,761,876 shares of Mersana Therapeutics Inc. common stock.
• This represents 3.0% of the total outstanding common stock of Mersana Therapeutics Inc.
• BlackRock holds sole voting power over 3,738,174 shares and sole dispositive power over 3,761,876 shares.
• This filing is Amendment No. 5 to Schedule 13G, indicating a change from previous beneficial ownership reports.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Mersana Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook.

Negatives

• Beneficial ownership by BlackRock, Inc. has decreased to 3.0% of Mersana Therapeutics Inc.'s common stock, falling below the 5% threshold that typically triggers an initial Schedule 13G filing, implying a reduction from a previously held stake exceeding 5%.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Key Dates

Keywords

Mersana Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor